RecruitingPhase 1

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

United States10 participantsStarted 2026-06-01

Plain-language summary

This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Anti-BCMA x CD3 bispecific antibody (for example: teclistamab, elranatamab)
. Anti-GPRC5d x CD3 bispecific antibody (for example: talquetamab)
. Anti-GPRC5d x CD3 x CD38 trispecific antibody
. Anti-BCMA x CD3 x CD38 trispecific antibody
. Anti-BCMA x CD3 x GPRC5d trispecific antibody
. Anti-BCMA chimeric antigen T-cell (for example: idecabtagene vicleucel, ciltacabtagene autoleucel)
. Anti-FcRL5 x CD3 bispecific antibody

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Phase Ib: Dose limiting toxicities (DLTs) as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Timeframe: From treatment initiation through 30 days post last dose of study treatment

Expansion Cohort: Participants change in the Teffector: Texhausted cell ratio

Timeframe: From treatment initiation through 3 months

Trial details

NCT IDNCT07581704

SponsorChristopher Strouse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-06-01

Contact for this trial

Christopher Strouse, MD

(319) 356-0489 christopher-strouse@uiowa.edu

View on ClinicalTrials.gov More Multiple Myeloma trials